All In Biotech

Drug Trial Radar · NCT07738614

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Jul 31, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.

Conditions

  • Obesity
  • Overweight

Interventions

  • EloralintideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

  • AcetaminophenDrug

    Administered Oral Solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acetaminophen Area Under the Concentration Versus Time Curve (AUC)Time frame: Baseline to Day 65
  2. Acetaminophen Maximum Observed Concentration (Cₘₐₓ)Time frame: Baseline to Day 65
  3. Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ)Time frame: Baseline to Day 65

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • ICON Early Phase Services

    San Antonio, Texas

  • Lilly Centre for Clinical Pharmacology

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.